Biomarkers and therapeutic targets for chronic kidney disease and sarcopenia

2021 Fiscal Year Final Research Report

• Project/Area Number: 20K16514
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 52010:General internal medicine-related
• Research Institution: Tokyo Medical and Dental University
• Principal Investigator: Mandai Shintaro 東京医科歯科大学, 医学部附属病院, 助教 (50824330)
• Project Period (FY): 2020-04-01 – 2022-03-31
• Keywords: 慢性腎臓病 / サルコペニア / 老化

Outline of Final Research Achievements

Chronic kidney disease (CKD) is a major public health problem that globally affects 700 million people. Emerging evidence has revealed the relationship between CKD and risks for cardiovascular disease, frailty, and sarcopenia, defined as a loss of muscle mass and strength, which impair healthspan and lifespan. However, molecular mechanism explaining the inter-organ communications between kidneys and skeletal muscle has yet to be determined. This study aimed to determine target molecules and biomarkers of sarcopenia in CKD model rodents and humans. The study findings would provide novel insights into the mechanisms and treatment strategies in CKD and sarcopenia.

Free Research Field

細胞生物学，腎臓病学，内科学

Academic Significance and Societal Importance of the Research Achievements

本研究の成果は2022年度内に複数の論文発表を予定している。これらの成果が，臨床応用の実現性の高い，サルコペニアの新たな治療戦略とバイオマーカー創出に繋がることが期待される。超高齢化社会を迎え，サルコペニア，フレイルの病態解明・克服は世界的に喫緊の課題である。今後のさらなる研究により，CKD患者の透析以外の新たな治療選択肢のみならず，健康寿命を延伸するためのバイオマーカー，治療薬シーズの同定を目指す。